GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant ...

On the downside, GSK's COVID-19 therapy Xevudy (sotrovimab) saw a slump in demand, with sales falling to £500 million from £1.3 billion in the first quarter of 2022, and GSK is expecting the ...

GSK’s shingles vaccine has been approved in the European Union for the prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN) in adults aged 50 years and older since 2018; and in adults 18 ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix for the prevention of shingles.

GSK managed to beat analysts’ revenue predictions ... driven once again by its shingles vaccine Shingrix and HIV therapies sold under the ViiV Healthcare joint venture. Shingrix grew 19% to ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK's Recombinant Zoster ...

The review by the EMA follows the U.S. Food and Drug Administration's (FDA) acceptance on January 8, 2025, of the same prefilled syringe for consideration. The vaccine, which has been available in ...

(IN BRIEF) GSK has announced that the European Medicines Agency (EMA) has accepted its regulatory application for a prefilled syringe presentation of Shingrix, its recombinant zoster vaccine (RZV) for ...

GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK's Recombinant Zoster Vaccine ...

Also in vaccines, GSK’s star Shingles vaccine Shingrix saw sales drop 4% at constant exchange rates to 848 million pound sterling ($1.06 billion) in the last three months of 2024. An overall ...

LONDON - GlaxoSmithKline PLC (LSE/NYSE: NYSE:GSK) announced today that the European Medicines Agency (EMA) has begun reviewing a prefilled syringe form of Shingrix, GSK's vaccine for shingles ...